Cigna’s first-quarter results contain a real tension: earnings improved, but operating cash flow weakened and one part of its pharmacy business became less profitable. That deserves investigation. It does not establish that the whole group is running out of cash or that a permanent collapse in pharmacy economics has already occurred.

The most useful distinction is between three questions: which businesses produced the earnings, why the cash conversion changed, and how much financial flexibility remains after investment and shareholder distributions.

Group growth masks different pharmacy outcomes

Quarterly revenue was $68.5 billion. Net income attributable to shareholders rose to $1.654 billion from $1.323 billion, approximately 25%. Adjusted income from operations rose to $2.058 billion from $1.840 billion, approximately 12%, while adjusted earnings per share increased to $7.79 from $6.74. These are different measures: the adjusted result excludes items identified in the company’s reconciliation, and EPS is also affected by the share count. The quarterly results provide both the GAAP figures and the adjustments.

Within Evernorth, Pharmacy Benefit Services reported adjusted revenue of $33.002 billion and adjusted pre-tax income of $394 million. A year earlier, the corresponding figures were $29.742 billion and $544 million. Revenue grew approximately 11%, while profit fell approximately 28%. Dividing those disclosed figures gives an adjusted pre-tax margin of about 1.19%, down from 1.83%.

Specialty and Care Services moved the other way. Adjusted revenue rose to $25.440 billion from $23.939 billion, and adjusted pre-tax income rose to $1.072 billion from $890 million. Its calculated margin increased to about 4.21% from 3.72%. These are segment-level adjusted margins, not GAAP group margins or a measurement of profit on each prescription. Segment revenue also cannot simply be added to reconstruct consolidated revenue without the company’s eliminations and other adjustments.

The contrast supports a narrow conclusion: specialty growth helped offset weaker pharmacy-benefit profitability. It does not support the broader claim that all pharmacy earnings are deteriorating.

Rebate reform is a genuine transition risk, with uncertain economics

Cigna attributed part of the pharmacy-benefit pressure to customer-affordability initiatives. Its quarterly filing describes proactive client renewals, investment in a rebate-free model and recontracting, including responses to the Inflation Reduction Act. Lower pharmacy claim volume was another negative contributor.

That disclosure makes the transition economically relevant. If clients pay less or contract structures change, Cigna must replace the lost economics through fees, service value, efficiency or growth. Investment and early renewals can also move costs and revenue between periods. What the filing does not establish is that the entire profit decline came from one programme or that the loss per prescription is permanent.

A useful future comparison would track pharmacy-benefit profit alongside claims volume, customer retention and disclosed transition costs. A rebound supported only by lower investment would mean something different from a recovery supported by stable customers and sustainable service fees. The original report does not disclose enough contract-level detail to calculate that outcome today.

The cash-flow decline is real; its cause needs care

Operating cash flow fell to $1.131 billion from $1.920 billion. Capital expenditure was $267 million, leaving approximately $864 million under the simple calculation of operating cash flow less capital expenditure. That calculation is not a forecast of annual distributable cash.

Cigna’s cash-flow discussion identifies several influences: adverse effects from the Inflation Reduction Act, lower insurance liabilities and the timing of manufacturer receivables, partly offset by other receivable movements and factoring. This supports scrutiny of the cash effects of the new system. It does not justify assigning the entire change to a single permanent collection delay.

Indeed, the cash-flow statement records a $4.570 billion outflow from the change in pharmacy and service costs payable. That contradicts a simple story in which this quarter’s operating cash flow was propped up by continuously stretching those payables. Large receivable and payable movements require analysis together; one balance or one cash-flow line is not the whole working-capital cycle.

The first negotiated Medicare maximum fair prices took effect on January 1, 2026, at the start of the quarter. They were not a future event at the article’s May publication date. CMS guidance sets out the manufacturer effectuation and refund process. Its payment timetable should not be reduced to a claim that every PBM automatically loses a fixed amount of cash for the same number of days.

Supplier finance is disclosed on the balance sheet

At March 31, obligations associated with Cigna’s supplier-finance programme were approximately $1.3 billion, down from $1.6 billion at year-end. The filing says these amounts were included in accounts payable and were predominantly associated with one supplier. They are not hidden off the balance sheet.

In this programme, participating suppliers may sell their receivables to financial institutions to receive payment earlier. This is different from Cigna selling its own receivables through factoring. The arrangements can affect cash-flow timing and create concentration or financing dependencies, so the disclosures matter. But the stated balance does not prove that loss of the programme would trigger an immediate, additional $1.3 billion payment by Cigna on top of obligations already recognised.

Likewise, current liabilities exceeding current assets is a signal to investigate the funding cycle, not a standalone insolvency finding. An insurer and pharmacy-services group has payment patterns unlike those of a manufacturer. The relevant tests include the maturity and reliability of receivables, the timing of obligations, access to liquidity and the ability to generate cash under less favourable conditions.

Separate operating performance from capital allocation

The quarter did not contain aggressive current-period share repurchases: the cash-flow statement reports no repurchases in the first quarter of 2026, compared with $1.508 billion a year earlier. Earlier repurchases can still reduce the weighted share count and support EPS. But the rise in total net income also shows that the entire earnings improvement cannot be attributed to a smaller denominator.

Cigna also repaid $550 million of debt during the quarter. Any assessment of near-term maturities must start with the March balance sheet and subsequent confirmed transactions, rather than reusing the prior year-end maturity schedule unchanged. Refinancing at higher rates is a reasonable scenario to test, not an event established by the existence of a maturity. The cash cost depends on the remaining principal, the debt actually refinanced and its contractual rate.

The insurance medical care ratio fell to 79.8% from 82.2%, with the HCSC divestiture materially changing the comparison. A lower consolidated ratio after a business disposal does not by itself show improved medical-cost control in the continuing book.

The investment question remains conditional

The bearish case is that weaker pharmacy-benefit margins persist while cash conversion remains difficult, leaving less room for investment, debt repayment and distributions. The favourable case is that specialty growth and durable service fees offset the transition, while the adverse cash movements ease.

Both cases can be tested through future disclosures. Neither requires speculation about an institution’s reason for changing a holding or an executive’s personal motives. For this quarter, the defensible conclusion is a mixed operating picture with weaker cash conversion—not a demonstrated liquidity crisis or a settled verdict on Cigna’s long-term value.